Critical Outcome Technologies Reports Fiscal 2015 Second Quarter Results
Highlighted by Development Milestones for COTI-2 as IND Filing Nears Completion
(firmenpresse) - LONDON, ONTARIO -- (Marketwired) -- 12/17/14 -- Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company") the biopharmaceutical company that uses machine learning to rapidly develop targeted therapies, reported its financial and operating results today for the three and six month periods ended October 31, 2014.
Highlights for the quarter included:
"We met several key milestones for our lead compound, COTI-2, during the second quarter," said Dr. Wayne Danter, Chief Executive Officer. "Positive results from critical pre-clinical experiments, along with additional funding from our recent financing, better position COTI-2 for the upcoming Phase 1 clinical trial. We continue to strengthen our relationship with MD Anderson and are pursuing opportunities for COTI-2 to make a difference in the treatment of other cancer indications beyond gynecological cancers. As we continue to prepare our IND submission, we also look forward to what should be a very exciting year for our Company and its investors in 2015."
Financial Results
The Company''s operational activities during the quarter were focused in three main areas; first, the completion of testing and preparation of the IND submission for COTI-2; second, financing efforts to fund the Phase 1 human trial of COTI-2 and the Company''s operations for the next year; and, third, business development initiatives. These activities resulted in the Company incurring a net loss of $946,204, or $0.01 per share, for the quarter compared to a net loss of $598,220, or $0.01 per share, for the second quarter a year earlier. For the six months ended October 31, 2014, the Company reported a loss of $1,917,000 or $0.02 per common share, compared to a loss of $1,098,273, or $0.01 per common share, for the same period last year. The increased loss for the quarter and year-to-date were attributable to increased expenses of $325,507 and $776,726 respectively in all functional expense areas but primarily research and development and general and administration.
Research and development expenditures increased $231,052 for the quarter and $332,749 year-to-date primarily reflecting the completion of the two-species toxicity studies, chemistry and manufacturing testing and analysis in support of the COTI-2 IND filing, and third party assistance in the preparation of the investigational new drug submission to the FDA.
General and administration ("G&A") expenditures increased $95,869 in the quarter and $443,326 year-to-date primarily related to professional fees and corporate governance costs supporting strategic advice and pursuit of financing in the U.S. Other activities that increased G&A expenditures included; investor relations activities in the U.S., support costs in obtaining the U.S. listing on the OTC trading platform, assistance with successfully obtaining the Orphan Drug Designation for COTI-2, information technology upgrades and strategic planning sessions.
Financing
During the quarter, the Company generated approximately $723,000 in gross proceeds to fund operations with approximately $522,000 from the first tranche of a non-brokered private placement with accredited investors and a further $201,000 from the exercise of warrants. Subsequent to the quarter end, the Company closed the second and third tranches of the private placement for aggregate gross proceeds from the total financing of approximately $2.628 million.
More detailed operating and financial results can be found in the Company''s Unaudited Condensed Interim Financial Statements and the Management Discussion and Analysis for the three and six month periods ended October 31, 2014, which can be found on SEDAR at or on the Company''s website at .
About Critical Outcome Technologies Inc. (COTI)
COTI is a biopharmaceutical company using machine learning to rapidly develop targeted therapies. COTI''s proprietary artificial intelligence platform, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.
Follow (at)CriticalOutcome on Twitter at .
Notice to Readers
Information contained in this press release may contain certain statements, which constitute "forward-looking statements" within the meaning of the Securities Act (Ontario) and applicable securities laws. For example, the statements "... continue to strengthen our relationship with MD Anderson and are pursuing opportunities for COTI-2 to make a difference in the treatment of other cancer indications beyond gynecological cancers" and "... continue to prepare our IND submission ..." are forward-looking statements. Forward-looking statements, by their nature, are not guarantees of future performance and are based upon management''s current expectations, estimates, projections and assumptions. COTI operates in a highly competitive environment that involves significant risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forward-looking statements. Management of COTI considers the assumptions on which these forward-looking statements are based to be reasonable, but as a result of the many risk factors, cautions the reader that actual results could differ materially from those expressed or implied in these forward-looking statements. Information in this press release should be considered accurate only as of the date of the release and may be superseded by more recent information disclosed in later press releases, filings with the securities regulatory authorities or otherwise.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
Tel: 519-858-5157
Email:
Heisler Communications
Trevor Heisler
Investor Relations
Tel: 416-500-8061
Email:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 17.12.2014 - 17:04 Uhr
Sprache: Deutsch
News-ID 1326075
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
LONDON, ONTARIO
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 134 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Critical Outcome Technologies Reports Fiscal 2015 Second Quarter Results
"
steht unter der journalistisch-redaktionellen Verantwortung von
Critical Outcome Technologies Inc. (COTI) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
